目的：评价泰能（伊米配能／西司他汀）治疗重度细菌性感染的临床疗效及安全性。方法：采用非对照开放试验研究，应用泰能治疗重度细菌性感染８３例，其中败血症１６例，感染性心内膜炎６例，下呼吸道感染５８例，皮肤软组织感染３例，应用泰能每次０５～１ｇ，每日２次，疗程５～１４ｄ，败血症及感染性心内膜炎延长到２０ｄ。结果：临床总有效率及细菌清除率均为８９１６％，不良反应发生率为１０８３％，ＭＩＣ值显示泰能对革兰氏阴性及革兰氏阳性细菌均具有高度抗菌活性。结论：泰能是治疗重度细菌性感染的有效、安全的抗菌药物 PURPOSE: To evaluate the clinical efficacy and safety of tirneam (imipenem / cilastatin) in the treatment of severe bacterial infections. Methods: In a non-controlled open-label trial, 83 cases of severe bacterial infections were treated with Tacine, including 16 sepsis, 6 infective endocarditis, 58 lower respiratory tract infections and 3 skin and soft tissue infections. Times 0  5 ~ 1g, 2 times a day, treatment of 5 ~ 14d, septicemia and infective endocarditis extended to 20d. Results: The total clinical effective rate and bacterial clearance rate were 8916% and the incidence of adverse reactions was 1083%. The MIC values ​​showed that Thalidomide had highly antibacterial activity against Gram-negative and Gram-positive bacteria. Conclusion: Tainon is an effective and safe antimicrobial agent for the treatment of severe bacterial infections